Omnicell, Inc. OMCL
At closeNov 5, 2026, 7:52 AM EST
Pre-market · Nov 5, 7:52 AM ET
- YTD
- -13.00%
- 1 year
- +10.27%
- Market cap
- 1.79B
- Revenue (ttm)
- 1.24B
- Profit margin
- 3.59%
- EPS (ttm)
- 0.96
- Shares out
- 45.48M
- P/E ratio
- 41.05
- Forward P/E
- 19.62
- YTD return
- -13.00%
- 1-year return
- +10.27%
- Volume
- 850.49K
- Avg volume
- 594.23K
- Open
- 36.54
- Previous close
- 35.46
- Day's range
- 36.54 – 39.63
- 52-week range
- 31.75 – 55.00
- Beta
- 0.89
- Analysts
- Strong Buy
- Price target
- 57.43 (+45.7%)
- Earnings date
- Feb 4, 2027
2Y -10.39 (-20.86%)
Key statistics
- Enterprise value
- 1.50B
- PEG ratio
- 15.40
- Price / sales
- 1.44
- Price / book
- 1.37
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -0.90%
- Free cash flow
- 155.97M
- Total cash
- 314.86M
- Total debt
- 189.67M
- Return on equity
- 3.52%
- Short % of float
- 8.68%
- 50-day average
- 34.64
- 200-day average
- 38.89
Analyst view
Consensus: strong buy
- Target (low)
- 50.00
- Target (mean)
- 57.43
- Target (high)
- 68.00
- Strong buy1
- Buy6
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate 0.42125.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 30, 2026 | 0.4213 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 0.4175 | 0.58 | +0.16 | +38.92% |
| Jul 30, 2026 | Jun 30, 2026 | 0.4675 | 0.94 | +0.47 | +101.07% |
| Apr 28, 2026 | Mar 31, 2026 | 0.33 | 0.55 | +0.22 | +66.67% |
| Feb 5, 2026 | Dec 31, 2025 | 0.47 | 0.40 | -0.07 | -14.89% |
| Oct 30, 2025 | Sep 30, 2025 | 0.36 | 0.51 | +0.15 | +41.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Freedom Capital Markets | main | Buy | Buy |
| Aug 3, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Jul 31, 2026 | Wells Fargo | main | Overweight | Overweight |
| Jul 31, 2026 | Keybanc | main | Overweight | Overweight |
| Apr 29, 2026 | Keybanc | main | Overweight | Overweight |
| Apr 23, 2026 | Wells Fargo | main | Overweight | Overweight |
About Omnicell, Inc.
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- omnicell.com
News
Why Omnicell (OMCL) is a Top Value Stock for the Long-Term Freedom Capital Markets Maintains Buy on Omnicell, Lowers Price Target to $55
Omnicell, Inc. (OMCL) Q3 2026 Earnings Call Transcript
Omnicell Q3 Earnings Call Highlights
Here's What Key Metrics Tell Us About Omnicell (OMCL) Q3 Earnings
Omnicell Q3 2026 Earnings Call Transcript
Omnicell (OMCL) Q3 Earnings and Revenues Top Estimates Omnicell Sees Q4 Adj EPS $0.41-$0.49 vs $0.37 Est; Sees Sales $295.000M-$301.000M vs $310.442M Est
Omnicell Raises FY2026 Adj EPS Guidance from $2.15-$2.30 to $2.48-$2.56 vs $2.27 Est; Narrows FY2026 Sales Guidance from $1.225B-$1.245B to $1.225B-$1.231B vs $1.237B Est
Omnicell Q3 Adj. EPS $0.58 Beats $0.42 Estimate, Sales $307.851M Beat $304.474M Estimate
Your note
Sign in to keep a note on OMCL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAUER JOANNE B | Director | Stock Award(Grant) | May 31, 2026 | 49,922 |
| ETTA NCHACHA | Chief Financial Officer | Stock Award(Grant) | Mar 6, 2025 | 132,023 |
| LIPPS RANDALL A | Chief Executive Officer | Sale | Jul 14, 2026 | 0 |
| MANLEY COREY J | Officer | Sale | May 17, 2026 | 112,783 |
| NJOKU NNAMDI | President | Sale | Aug 16, 2026 | 161,224 |
| NUTT BRIAN H | Officer | Stock Award(Grant) | Mar 31, 2026 | 23,085 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.58% | 7,539,602 | 297.14M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 6.93% | 3,151,350 | 124.19M | Jun 29, 2026 |
| Wellington Management Group, LLP | 5.94% | 2,700,603 | 106.43M | Jun 29, 2026 |
| Dimensional Fund Advisors LP | 5.39% | 2,452,443 | 96.65M | Jun 29, 2026 |
| State Street Corporation | 4.59% | 2,085,723 | 82.20M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.33% | 1,970,472 | 77.66M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.97% | 2,714,312 | 106.97M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 1,368,386 | 53.93M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.60% | 1,181,613 | 46.57M | Sep 29, 2026 |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 2.56% | 1,162,437 | 45.81M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.18% | 989,975 | 39.01M | Jun 29, 2026 |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 1.43% | 649,081 | 25.58M | Sep 29, 2026 |
